6505-- Denosumab Injections
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The VA National Acquisition Center intends to issue an unrestricted Request for Proposal (RFP) 36E79726R0018 for Denosumab Injections. This procurement aims to secure an uninterrupted source of supply for the Department of Veterans Affairs (VA), Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The solicitation is expected around April 17, 2026, with a tentative closing date of May 5, 2026.
Scope of Work
This contract will cover the supply of:
- Denosumab 60MG Injection: Estimated annual usage of 22,737 vials/syringes.
- Denosumab 120MG Injection: Estimated annual usage of 5,472 vials/syringes.
Offerors must provide the exact drug name as it appears on the label and possess a unique NDC number. The offeror's label with its unique NDC must be the sole label on the product. Contract items will be distributed via the VA's and DoD's Pharmaceutical Prime Vendor Programs.
Contract Details
- Contract Type: Commercial item format, in accordance with FAR Part 12.
- Contract Period: One base year plus four pre-priced one-year option periods.
- NAICS Code: 325412 (Drugs And Biologicals).
Eligibility & Requirements
- Set-Aside: Unrestricted procurement.
- Covered Drugs: For covered drugs (as defined in 38 U.S.C. § 8126), offerors must have an executed Master Agreement (MA) and Pharmaceutical Pricing Agreement (PPA) on file with the VA National Acquisition Center, FSS, including the offered NDCs. Established Federal Ceiling Prices (FCPs) must be associated with the offeror's FSS contract or interim agreement by the solicitation's due date.
- Biosimilar Products: Proposed biosimilars must be FDA licensed under 42 U.S.C. § 262, meet all biosimilar criteria, and be listed as biosimilar to the innovator in the FDA Purple Book.
- Product Presentation: If both vial and syringe presentations are marketed for the same product strength, both must be included in the offer at the same proposed price.
Submission & Evaluation
- The solicitation (RFP 36E79726R0018) will be issued electronically on SAM.gov around April 17, 2026.
- Tentative Closing Date: May 5, 2026.
- No paper copies will be available; offerors must monitor SAM.gov for updates and amendments.
- All responsible sources may submit an offer.
Point of Contact
For questions, contact Ray Roldan, Contract Specialist, at Raymond.Roldan@va.gov or 708-786-4930.